New Anti-VEGF Agent Brolucizumab Shows Promise for AMD

Matt R. Starr, MD; Sophie J. Bakri, MD


October 12, 2017


This study sought to determine whether brolucizumab was noninferior to aflibercept in regard to change in visual acuity, which it was. It also demonstrated stable visual acuity in half of the patients receiving brolucizumab at 12-week intervals.

What does this mean for clinicians?

Patients can be treated with brolucizumab and achieve improvements in vision and decreases in central subfield thickness similar to those of patients receiving aflibercept. The study also makes a valid argument for increased dosing intervals for patients receiving brolucizumab, as almost half of those patients had stable visual acuities after the second 12-week interval. Still, there was an overall trend toward a decline in vision, which the authors attributed to seven patients who probably needed an unscheduled injection but never received additional injections.

This well-designed phase 2 clinical trial shows that brolucizumab can be a first-line agent for neovascular AMD. As far as being a unique agent that can be used at longer interval doses, however, more data and longer follow-up are needed to accurately assess whether a 12-week cycle with brolucizumab is comparable to 8-week cycles of other anti-VEGF agents.


Follow Medscape on Twitter: @Medscape


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.